Tivic Health CEO Jennifer Ernst to Present at New York BioFuture 2024
Tivic Health Systems (Nasdaq: TIVC) announced CEO Jennifer Ernst will present at BioFuture 2024 in New York, October 28-30. The presentation, scheduled for October 29 at 2:30 p.m. EDT, will showcase the company's advancements in bioelectronic medicine and recent data on vagus nerve stimulation.
The conference features prominent speakers including Dr. Kevin Tracey from The Feinstein Institutes for Medical Research, Tivic's clinical partners. The event will explore how vagus nerve stimulation is transforming treatments for conditions like rheumatoid arthritis, Crohn's disease, cancer, diabetes, and mental health. One-on-one meetings with investors are available through the BioFuture Showcase Partnering Platform, with a virtual component following November 5-7.
Tivic Health Systems (Nasdaq: TIVC) ha annunciato che il CEO Jennifer Ernst presenterà al BioFuture 2024 a New York, dal 28 al 30 ottobre. La presentazione è programmata per il 29 ottobre alle 14:30 EDT e metterà in evidenza i progressi dell'azienda nella medicina bioelettronica e i recenti dati sulla stimolazione del nervo vago.
La conferenza ospita relatori di spicco, tra cui il Dr. Kevin Tracey delle Feinstein Institutes for Medical Research, partner clinici di Tivic. L'evento esplorerà come la stimolazione del nervo vago sta trasformando i trattamenti per condizioni come l'artrite reumatoide, la malattia di Crohn, il cancro, il diabete e la salute mentale. Sono disponibili incontri one-to-one con gli investitori attraverso la BioFuture Showcase Partnering Platform, con un componente virtuale che seguirà dal 5 al 7 novembre.
Tivic Health Systems (Nasdaq: TIVC) anunció que la CEO Jennifer Ernst presentará en el BioFuture 2024 en Nueva York, del 28 al 30 de octubre. La presentación, programada para el 29 de octubre a las 2:30 p.m. EDT, mostrará los avances de la empresa en medicina bioelectrónica y datos recientes sobre la estimulación del nervio vago.
La conferencia contará con destacadas intervenciones, incluyendo al Dr. Kevin Tracey de los Feinstein Institutes for Medical Research, socios clínicos de Tivic. El evento explorará cómo la estimulación del nervio vago está transformando los tratamientos para condiciones como la artritis reumatoide, la enfermedad de Crohn, el cáncer, la diabetes y la salud mental. Se ofrecerán reuniones individuales con inversores a través de la plataforma de asociación de BioFuture Showcase, con un componente virtual que seguirá del 5 al 7 de noviembre.
티빅 헬스 시스템즈 (Nasdaq: TIVC)는 CEO 제니퍼 에른스트가 10월 28일부터 30일까지 뉴욕에서 열리는 바이오퓨처 2024에 참석할 것이라고 발표했습니다. 발표는 10월 29일 오후 2시 30분 EDT로 예정되어 있으며, 회사의 생체전자 의학 발전과 미주 신경 자극에 대한 최근 데이터를 소개할 것입니다.
이번 컨퍼런스에는 티빅의 임상 파트너인 파인스타인 의학 연구소의 케빈 트레이시 박사가 포함된 저명한 연사들이 참석합니다. 이 행사는 미주 신경 자극이 류마티스 관절염, 크론병, 암, 당뇨병 및 정신 건강과 같은 질환 치료에서 어떻게 혁신을 일으키고 있는지 탐구할 것입니다. BioFuture Showcase 파트너링 플랫폼을 통해 투자자와의 1:1 미팅이 가능하며, 11월 5일부터 7일 사이에 가상 구성 요소도 제공됩니다.
Tivic Health Systems (Nasdaq: TIVC) a annoncé que la PDG Jennifer Ernst présentera au BioFuture 2024 à New York, du 28 au 30 octobre. La présentation, prévue pour le 29 octobre à 14h30 EDT, mettra en avant les avancées de l'entreprise dans le domaine de la médecine bioélectronique et des données récentes sur la stimulation du nerf vague.
La conférence accueillera des intervenants de renom, dont le Dr Kevin Tracey des Feinstein Institutes for Medical Research, partenaires cliniques de Tivic. L'événement explorera comment la stimulation du nerf vague transforme les traitements pour des affections telles que l'arthrite rhumatoïde, la maladie de Crohn, le cancer, le diabète et la santé mentale. Des réunions individuelles avec des investisseurs sont disponibles via la plateforme de partenariat BioFuture Showcase, avec un composant virtuel qui suivra du 5 au 7 novembre.
Tivic Health Systems (Nasdaq: TIVC) gab bekannt, dass die CEO Jennifer Ernst beim BioFuture 2024 in New York vom 28. bis 30. Oktober präsentieren wird. Die Präsentation, die für den 29. Oktober um 14:30 Uhr EDT geplant ist, wird die Fortschritte des Unternehmens in der bioelektronischen Medizin und aktuelle Daten zur Vagusnerv-Stimulation vorstellen.
Die Konferenz bietet namhafte Referenten, darunter Dr. Kevin Tracey von den Feinstein Institutes for Medical Research, den klinischen Partnern von Tivic. Die Veranstaltung wird untersuchen, wie die Vagusnerv-Stimulation die Behandlungen für Erkrankungen wie rheumatoide Arthritis, Morbus Crohn, Krebs, Diabetes und psychische Gesundheit transformiert. Eins-zu-eins-Meetings mit Investoren sind über die BioFuture Showcase Partnering Platform erhältlich, mit einer virtuellen Komponente, die vom 5. bis 7. November folgt.
- None.
- None.
- Presentation will highlight Tivic Health’s recent advancements in vagus nerve stimulation -
“This year, BioFuture 2024 has a strong focus on bioelectronic medicine, with industry leaders taking the stage,” highlighted Jennifer Ernst, CEO of Tivic Health. “We are pleased to be included in the event, that leads off with a Fireside Chat with Dr. Kevin Tracey, a pioneer in the field of bioelectronic medicine and CEO & President of The Feinstein Institutes for Medical Research – our clinical partners in development of our vagus nerve stimulation platform. Further reinforcing the importance of this field, Dr Tracey’s presentation will be followed by an industry panel on the promise of neuromodulation for therapeutic care. These are strong indicators of the growing investor and clinical interests in bioelectronic medicine and specifically in vagus nerve stimulation.”
According to BioFuture 2024, these sessions will explore how vagus nerve stimulation “is revolutionizing treatment of conditions such as Rheumatoid arthritis, Crohn’s disease, even cancer, diabetes and mental health conditions.”
Jennifer Ernst will be available for one-on-one meetings with potential investors and partners through the BioFuture Showcase Partnering Platform via this link: https://www.hellopartnering.com/home, or by contacting Tivic Health at: ir@tivichealth.com. A virtual component will follow from November 5-7, offering global attendees access to recorded sessions and additional virtual one-on-one meetings.
About Tivic Health Systems, Inc.
Tivic Health is a commercial health tech company advancing the field of bioelectronic medicine. Tivic Health’s patented technology platform leverages stimulation on the trigeminal, sympathetic, and vagus nerve structures. Tivic Health’s non-invasive and targeted approach to the treatment of inflammatory chronic health conditions gives consumers and providers drug-free therapeutic solutions with high safety profiles, low risk, and broad applications. Tivic Health’s first commercial product ClearUP is an FDA approved, handheld bioelectronic sinus device available through online retailers and commercial distributors. For more information visit http://tivichealth.com @TivicHealth
Forward-Looking Statements
This press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems, Inc.’s current expectations and are subject to inherent uncertainties, risks, and assumption that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health’s filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, under the heading “Risk Factors”; as well as the company’s subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241024729280/en/
Media Contact:
Morgan Luke
Morgan.Luke@tivichealth.com
Investor Contact:
Hanover International, Inc.
ir@tivichealth.com
Source: Tivic Health Systems, Inc.
FAQ
When is Tivic Health (TIVC) presenting at BioFuture 2024?
What will Tivic Health (TIVC) discuss at BioFuture 2024?
How can investors meet with Tivic Health (TIVC) at BioFuture 2024?
What conditions can Tivic Health's (TIVC) vagus nerve stimulation potentially treat?
